QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.106.115436v1 321/3/1154    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rao, N. L. Articles by Fourie, A. M. Search for Related Content PubMed PubMed Citation Articles by Rao, N. L. Articles by Fourie, A. M.

INFLAMMATION, IMMUNOPHARMACOLOGY, AND ASTHMA

Anti-Inflammatory Activity of a Potent, Selective Leukotriene A₄ Hydrolase Inhibitor in Comparison with the 5-Lipoxygenase Inhibitor Zileuton

Johnson and Johnson Pharmaceutical Research and Development L.L.C., San Diego, California

Leukotriene A₄ hydrolase (LTA₄H) catalyzes production of the proinflammatory lipid mediator, leukotriene (LT) B₄, which is implicated in a number of inflammatory diseases. We have identified a potent and selective inhibitor of both the epoxide hydrolase and aminopeptidase activities of recombinant human LTA₄H (IC₅₀, approximately 10 nM). In a murine model of arachidonic acid-induced ear inflammation, the LTA₄H inhibitor, JNJ-26993135 (1-[4-(benzothiazol-2-yloxy)-benzyl]-piperidine-4-carboxylic acid), dose-dependently inhibited ex vivo LTB₄ production in blood, in parallel with dose-dependent inhibition of neutrophil influx (ED₅₀, 1–3 mg/kg) and ear edema. In murine whole blood and in zymosan-induced peritonitis, JNJ-26993135 selectively inhibited LTB₄ production, without affecting cysteinyl leukotriene production, while maintaining or increasing production of the anti-inflammatory mediator, lipoxin (LX) A₄. The 5-lipoxygenase (5-LO) inhibitor zileuton showed inhibition of LTB₄, LTC₄, and LXA₄ production. Although zileuton inhibited LTB₄ production in the peritonitis model more effectively than the LTA₄H inhibitor, the influx of neutrophils into the peritoneum after 1 and 2 h was significantly higher in zileuton- versus JNJ-26993135-treated animals. This difference may have been mediated by the increased LXA₄ levels in the presence of the LTA₄H inhibitor. The selective inhibition of LTB₄ production by JNJ-26993135, while increasing levels of the anti-inflammatory mediator, LXA₄, may translate to superior therapeutic efficacy versus 5-LO or 5-LO-activating protein inhibitors in LTB₄-mediated inflammatory diseases.

Address correspondence to: Anne M. Fourie, Johnson and Johnson Pharmaceutical Research and Development, 3210 Merryfield Row, San Diego, CA 92121. E-mail: afourie{at}prdus.jnj.com

This article has been cited by other articles:

				J. A. Cottrell and J. P. O'Connor Pharmacological Inhibition of 5-Lipoxygenase Accelerates and Enhances Fracture-Healing J. Bone Joint Surg. Am., November 1, 2009; 91(11): 2653 - 2665. [Abstract] [Full Text] [PDF]

				M. Deruaz, A. Frauenschuh, A. L. Alessandri, J. M. Dias, F. M. Coelho, R. C. Russo, B. R. Ferreira, G. J. Graham, J. P. Shaw, T. N.C. Wells, et al. Ticks produce highly selective chemokine binding proteins with antiinflammatory activity J. Exp. Med., September 1, 2008; 205(9): 2019 - 2031. [Abstract] [Full Text] [PDF]